Clinical Trial

A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The primary purpose of this study is to evaluate the anti-tumor activity of TLN-254 monotherapy in participants with relapsed or refractory T-cell lymphoma.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2024-12-10; most recent amendment 2025-10-09.
Status change: Not Yet Recruiting → Recruiting 2024-12-19
Trial Details
NCT Number NCT06733441
Lead Sponsor Treeline Biosciences, Inc.
Conditions Lymphoma
Enrollment 50 participants
Start Date 2024-12-16
Primary Completion 2026-11-15 (estimated)
Study Completion 2028-11-15 (estimated)
Updated on ClinicalTrials.gov 2025-10-10